American court confirms Atrium's exclusive US rights to the renowned Wobenzym[R]N.

Atrium Innovations, Inc. is pleased to announce that, following an American court decision, the company has received approval to sell its enzyme supplement Wobenzym[R]N in the United States. Marlyn Nutraceuticals, Inc., located in Phoenix, Arizona, has been ordered by the US District Court to immediately stop using the Wobenzym[R]N trademark and selling products under this name.

Wobenzym[R]N was initially developed more than 40 years ago by Mucos Pharma GmbH & Co., a company acquired by Atrium in July 2007. Wobenzym[R]N is an enzyme-based product well known within the medical community in Germany and certain Eastern European countries for its numerous benefits for the health of joints, muscles, and tendons as well as for the immune system. As one of the top-selling joint and muscle health products in these countries, Wobenzym[R]N garners current annual sales of over US $90 million.

"We are very pleased with court ruling, which will allow us to start selling Wobenzym[R]N in the United States immediately and with no restrictions," stated Pierre Fitzgibbon, President and Chief Executive Officer of Atrium Innovations. "This high-quality product, sold as an enzyme supplement in the US, offers a natural solution to very common conditions such as joint and muscle discomfort. Through our two American subsidiaries, Douglas Laboratories and Pure Encapsulations, which serve some 40,000 health care professionals in the US, we have gained in-depth knowledge of this marked, and this edge will allow us to rapidly commercialize Wobenzym[R]N. We also intend to draw on other specialize distribution networks that offer strong business potential. This decision signifies a major development for Atrium and will allow the company to accelerate its growth and development in the United States."

For more information on Wobenzym[R]N, please visit www.wobenzym-usa.com.